Rensselaer, NY, September 30, 2024 – Taconic Biosciences was awarded the 2024 Novel Product Award at the 26th Annual Merck Technology Symposium. The award, presented by Planet Connect, recognized the FcResolv® NOG Portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors which are known to confound results in antibody-based therapy studies.
“It is truly an honor to receive this award recognizing Taconic’s innovative contributions to advancing critical healthcare research from idea to cure,” said Nancy J. Sandy, Chief Executive Officer of Taconic Biosciences. “Taconic FcResolv® NOG mouse models deliver significant advantages to in vivo researchers. They dramatically advance antibody-based therapy development by removing false positives or false negatives that might otherwise eliminate promising drug candidates.”
FcResolv® NOG models, launched in collaboration with the Central Institute for Experimental Medicine and Life Science (CIEM) in Japan, afford investigators greatly improved accuracy in efficacy studies due to functional knockout of murine FcɣR activity. The platform is ideal for investigating any indication utilizing a therapy incorporating an Fc domain, applicable to research fields like immuno-oncology, autoimmune disease, infectious disease, regenerative medicine, and more.
Antibody-based therapies represent one of the fastest-growing drug classes, creating a pressing need for better preclinical tools to assess therapeutics such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. The Taconic FcResolv® NOG portfolio enables researchers to evaluate drug candidates like these on their own merits, free of interference from residual murine Fc gamma receptors activity.
To learn more about the FcResolv NOG portfolio, visit Taconic.com/FcResolv. Or call 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.
